Recro Pharma (NASDAQ:REPH) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Thursday.
A number of other brokerages also recently weighed in on REPH. ValuEngine upgraded Recro Pharma from a “hold” rating to a “buy” rating in a report on Wednesday, April 18th. CIBC initiated coverage on Recro Pharma in a report on Wednesday, February 14th. They issued an “outperform” rating and a $19.00 price target for the company. Berenberg Bank initiated coverage on Recro Pharma in a report on Thursday, April 19th. They issued a “buy” rating for the company. Zacks Investment Research upgraded Recro Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, March 21st. Finally, Oppenheimer started coverage on Recro Pharma in a research note on Tuesday, February 13th. They set an “outperform” rating and a $19.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $14.21.
Shares of Recro Pharma opened at $5.97 on Thursday, according to MarketBeat.com. Recro Pharma has a twelve month low of $5.81 and a twelve month high of $13.05. The company has a quick ratio of 1.55, a current ratio of 1.78 and a debt-to-equity ratio of 2.20. The company has a market capitalization of $261.06 million, a PE ratio of -2.90 and a beta of -0.75.
Recro Pharma (NASDAQ:REPH) last issued its quarterly earnings results on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.65) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.68) by $0.03. Recro Pharma had a negative return on equity of 105.78% and a negative net margin of 74.85%. The business had revenue of $19.54 million during the quarter, compared to the consensus estimate of $17.32 million. equities analysts forecast that Recro Pharma will post -4.09 EPS for the current year.
In related news, major shareholder Healthcare Master Fun Broadfin sold 200,000 shares of the company’s stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $10.07, for a total transaction of $2,014,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 21.60% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Lyon Street Capital LLC grew its stake in Recro Pharma by 182.6% during the 1st quarter. Lyon Street Capital LLC now owns 1,027,271 shares of the specialty pharmaceutical company’s stock worth $11,310,000 after buying an additional 663,776 shares during the last quarter. BlackRock Inc. boosted its position in Recro Pharma by 1.4% during the 4th quarter. BlackRock Inc. now owns 1,011,855 shares of the specialty pharmaceutical company’s stock worth $9,359,000 after acquiring an additional 13,799 shares during the period. Sphera Funds Management LTD. acquired a new position in Recro Pharma during the 1st quarter worth $4,010,000. Millennium Management LLC acquired a new position in Recro Pharma during the 1st quarter worth $3,060,000. Finally, The Manufacturers Life Insurance Company boosted its position in Recro Pharma by 6,480.5% during the 1st quarter. The Manufacturers Life Insurance Company now owns 235,712 shares of the specialty pharmaceutical company’s stock worth $2,595,000 after acquiring an additional 232,130 shares during the period. Hedge funds and other institutional investors own 56.15% of the company’s stock.
Recro Pharma Company Profile
Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.